Connect your AI

Cumberland Pharmaceuticals CPIX Price / book

Price / book at other companies

Baxter InternationalBAX

1.4×-1.0×

PTH

Pelthos Therapeutics Inc.PTHS

2×—

Rigel PharmaceuticalsRIGL

1.2×-16.1×

RFL

Rafael Holdings, Inc.RFL

0.9×+0.1×

Opko HealthOPK

0.7×-0.1×

OrganonOGN

1.7×-5.4×

Other financials

Income statement

Revenue$9.1M-22.0%

Gross profit$7.2M-30.0%

Operating income-$3.1M-342%

Net income-$3.3M-362%

EPS (diluted)-$0.22-375%

Balance sheet

Cash & equivalents$11.0M-27.1%

Total debt$4.8M-7.1%

Total equity$21.6M-24.5%

Total assets$71.0M+1.5%

Cash flow

Operating cash flow$387.0K-90.1%

CapEx--100%

Free cash flow$387.0K-89.9%

Valuation

Market cap$97.09M+142%

Enterprise value$90.91M+212%

P/S2.3×+1.4×

Profitability

Gross margin82.9%-1.4pp

Operating margin-17.2%-125pp

Net margin-17.6%-103pp

FCF margin3.3%—

Returns & leverage

Return on equity-29.4%-86.3pp

Debt / equity0.2×0.0×

Current ratio1×-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

market cap/total stockholders equity=2.2×

Based on the most recent quarter.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Cumberland Pharmaceuticals's price / book?: Cumberland Pharmaceuticals (CPIX) reported price / book of 2.2× in Q1 2026.
How has Cumberland Pharmaceuticals's price / book changed year-over-year?: Cumberland Pharmaceuticals's price / book increased by 9.0% year-over-year, from 2.1× to 2.2×.
What is the long-term trend for Cumberland Pharmaceuticals's price / book?: Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's price / book has grown at a 20.5% compound annual growth rate (CAGR), from 0.9× to 2.4×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.